Last reviewed · How we verify
NCT06838286: TRIO
Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
trial testing SGLT2 inhibitor in Diabetes Mellitus, Type 2 in 10,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Chong Kun Dang Pharmaceutical |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 16 March 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- SGLT2 inhibitor — full drug profile →
- Thiazolidinedione — full drug profile →
- DPP-4 inhibitor — full drug profile →
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Chong Kun Dang Pharmaceutical — full company profile →
Who can join
19 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06838286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT2 inhibitor
Trials testing the same drug.
- NCT07360457 — GLP1 Analogues and the Risk of Osteoarthritis · not yet recruiting
- NCT07172971 — Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy · Phase 1 · not yet recruiting
- NCT07334145 — Effect of SGLT2 Inhibitors on Anemic CKD Patients · not yet recruiting
- NCT07063316 — SGLT2 Inhibitors and Renal Anemia in Japan: RWD · active not recruiting
- NCT06350487 — The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction · Phase 4 · not yet recruiting
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Chong Kun Dang Pharmaceutical trials
Trials by the same sponsor.
- NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
- NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
- NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
- NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06838286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
- Last refreshed: 20 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06838286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing